loader2
Login Open ICICI 3-in-1 Account
Open ICICI 3-in-1 Account

Tarsons Products Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Tarsons Products Ltd. 12 Aug 2025 14:11 PM
Result PDF

Q1FY26 Quarterly Result Announced for Tarsons Products Ltd.

Medical Equipment company Tarsons Products announced Q1FY26 results

  • Revenue: Rs 91.4 crore compared to Rs 84.8 crore during Q1FY25, change 8%.
  • EBITDA: Rs 24.7 crore compared to Rs 18.8 crore during Q1FY25, change 32%.
  • EBITDA Margin: 27.0% for Q1FY26.
  • PAT: Rs 1.8 crore compared to Rs 4.0 crore during Q1FY25, change -56%.
  • PAT Margin: 2.0% for Q1FY26.

Aryan Sehgal, Promoter & Whole Time Director of Tarsons, said: We are pleased to report a YoY revenue growth of 10% and an EBITDA growth of 31% on a standalone basis. Domestic revenues in Q1FY26 saw a healthy uptick of approximately 12%, reflecting early signs of recovery in the life sciences industry and our ability to capture increased market share. While these signs of revival remain somewhat volatile, the current order pipeline and ongoing customer inquiries give us confidence in sustaining growth through FY26 and beyond.

Profit After Tax for the current period was impacted due to accelerated depreciation following the capitalisation of our new facility. However, as revenue contribution from this plant ramps up, we expect to benefit from strong operating leverage, leading to improved overall EBITDA and PAT in the coming periods. Our Cash PAT in the interim grew by 38% on a standalone basis & by 44% on consolidated levels.

With the addition of new product categories enabled by the commissioning of our new facility at Panchla, we will be positioned to address a broader market, supporting our growth ambitions and helping us outperform industry trends. Backed by the strong brand equity of Tarsons and our extensive pan-India distribution network, we are optimistic about achieving similar market share in these new categories as we currently command for our existing product portfolio.

We remain committed to the industry's long-term growth prospects and have continued to invest through the down cycle to strengthen our capacities and capabilities, positioning ourselves for sustainable growth over the next 3–5 years. Backed by the strong brand equity of Tarsons and our consistent track record of delivering high-quality products, we are confident in our ability to capture greater market share in our existing product lines while accelerating the adoption of our newly introduced offerings.”

Result PDF

Result PDF

Plastic products firm Tarsons Products announced Q3FY23 results:

  • Q3FY23 & 9MFY23:
    • Revenues for Q3FY23 & 9MFY23 were lower by 13% & 7% respectively, dip in revenues was on account of:
      • Temporary slowdown in the life science industry, since the industry is yet recovering from the after-effects of the covid pandemic.
      • Loss in revenues related to covid pandemic as compared to the previous financial year, however, our conventional business revenues have shown resilience & are expected to pick up.
    • EBITDA margins for the Q3FY23 stood at 43.5% & for 9MFY23 stood at 45%,dip in the margins were on account of:
      • Lower absorption of fixed cost on account of decline in revenues
      • Higher spends on sales promotion, marketing & travelling expenses to fuel future growth in domestic & export markets.
    • Update on our upcoming Capex (New manufacturing capacities at Panchla, West Bengal):
      • Capex plan is as per the schedule and we do not see any major deviation from our timelines.
      • We remain optimistic about the industry growth prospects, with the addition of new product categories & capacity expansion we envisage reaching greater heights.
      • Manufacturing at the new facilities will begin in phases starting from Q2FY24.

Commenting on the Q3 FY23 performance of the company Mr. Rohan Sehgal, Whole Time Director for Tarsons, said: “Our revenues for Q3FY23 were lower by 13% on a YoY basis, this decline was majorly attributable to external macro-economic factors & overall slow down in the life science industry. Impact on revenues was also on account of high base of covid related revenues in FY22, which was replaced by our conventional business to a significant extent in the current financial year.

Due to political uncertainty and growing recessionary trends, our export revenues declined by 17% during the quarter and remained flat for 9MFY23. These are difficult times for not only our industry, but for the entire world, and we are standing firm and attempting to sail through these challenging times.

Our capacity expansion is proceeding smoothly, and commissioning is scheduled for Q2FY24. These capabilities would propel the company's next phase of expansion, which would include the addition of high-value products, which would further strengthen the "Tarsons" brand.

We believe that these market conditions are temporary in nature and in the long term we see the plastic labware market continue to grow both domestically and internationally and so will Tarsons.”

Result PDF

Plastic Product manufacturer Tarsons Products announced Q2FY23 results:

  • Revenue for Q2FY23 stood at Rs 71.2 crore as compared to Rs 76.0 crore in Q2FY22
  • The dip in the revenue was on account of the high share of covid related revenues during H1FY22
  • EBIDTA for Q2FY23 stood at Rs 32.7 crore as compared to Rs 38.5 crore in Q2FY22
  • EBIDTA margins have been impacted on account of manpower costs for upcoming facility & Marketing & Branding expenses in the exports markets to fuel  future growth engines

Commenting on the Q2FY23 performance of the company, Rohan Sehgal said: “Our revenues for Q2FY23 were down by 6% on a YoY basis and up by 4% on a QoQ basis. If we compare on a like-to-like basis, i.e. negating the high base of covid related revenues in H1FY22, our conventional business has shown substantial growth. In addition, our product portfolio and a wide network of distributors across India. We are confident of sustaining our growth in the domestic conventional business. Our export revenues have grown by 11% & 12% for Q2 & H1FY23 respectively. With expanding product portfolio and the Brand & Trust, Tarsons has developed over the last four decades. We are confident of expanding our footprints in the global markets. Our capacity expansion is on track and the commissioning of the upcoming facility is expected to be in H1FY24. We are confident of ramping up this facility in a short span because Tarsons as a brand has grown in popularity for quality products and timely delivery. Our strategy is to be present in all business segments of the life science industry, gain a significant share of the Indian market, and strengthen our presence in the export markets.”

 

Result PDF

Plastic products firm Tarsons Products announced Q1FY23 Result :

  • Q1FY22 i.e. April to June 2021 witnessed higher share of sales on account of second wave of Covid.
  • The Revenue contribution from conventional business in Q1FY22 was lower due to the demand from other life science industry on account of lockdowns and reduced activities.
  • Q1FY23 witnessed a normalized quarter with healthy growth and higher contribution from conventional business. On a like-to-like basis, our conventional business has witnessed YoY  growth.
  • Gross margin in Q1FY23 was impacted due to change in product mix and inflationary commodity environment on account of geo political tensions and supply chain disruptions.
  • EBIDTA margins in Q1FY23 were also impacted on account of higher expenses due to traveling and participation in fare & exhibitions and higher investments in manpower to support future growth.

Commenting on the Q1 FY23 performance of the company Mr. Rohan Sehgal Said: “Revenue for Q1FY23 was muted on account of higher share of Covid related revenues which contributed significantly in Q1FY22. However, despite negligible contribution from covid related revenues in Q1FY23 your company has been able to deliver revenues at par on Y-o-Y basis. We have been participating in various fare & exhibitions in the exports markets to mark our presence as a leading suppliers of labware products of global standards and quality. We have been receiving positives responses & enquires and are optimistic of higher demand from international markets going forward.

Our expansion of new facilities is on track and progressing well, we believe with the new facilities, addition of new product portfolio and trusted brand for “TARSONS” in the life science community, we are optimistic about the new phase of growth of your company. Our focus remains on brand building, deliver quality products, automation of processes and improve export presence and we continue to work in that direction.”

 

Result PDF

Plastic Products company Tarsons Products declares Q3FY22 result:

          Q3FY22 :

  • Revenue from Operations Rs. 71 crores
  • Gross Profit Rs. 55 crores
  • EBIDTA Rs. 33 crores 
  • Profit after Tax Rs. 22 crores
  • Revenue contribution from exports has increased from 31% in Q3FY21 to 41% in Q3FY22
    9MFY22 :
  • Revenue from Operations Rs. 216 crores
  • Gross Profit Rs. 172 crores
  • EBIDTA Rs. 108 crores
  • Profit after Tax Rs. 71 crores

Commenting on the Q3 & 9MFY22 performance of the company Mr. Rohan Sehgal Said: “We are delighted to post strong revenue & profitability growth for Q3 & JMFY22 on the back of strong demand for our products across the end user industry. Revenue for 9WFY22 grew by 34% and PAT for 9MFY22 grew by 57% on YoY basis. Our domestic business witnessed strong momentum with demand for our products and wallet share addition across customers increasing on month on month basis. Our export business also grew by ~42% for 9MFY22 as compared to the same period last year.

Going forward, we are optimistic of the demand scenario from the domestic and the overseas market and our product diversification strategy coupled with addition of wallet share from the existing customers helps us to maintain a positive outlook on the revenue growth and profitability. Our expansion plans with new facility and upgradation of capabilities in the existing plants is on track and should be operational by middle of FY23 At Tarsons, we believe in Trust & Quality which will help us to capture higher market share in the growing plastic labware market Moving forward, we also reiterate our confidence in our ability to sustain Company’s delivery of outstanding shareowner value”

Result PDF

Trending News

RBI will buy ₹2 lakh cr securities, launches dollar swap auction

The Reserve Bank of India on Tuesday said it will purchase government securities worth ₹2 lakh crore and conduct a $10 billion buy/sell dollar-rupee swap auction to inject liquidity in the banking system.

Published on 24-Dec-2025 09:09

Tata Motors launches Avinya EV brand

Tata Motors plans to formally roll out its new Avinya premium EV brand by the end of 2026, positioning it above its existing Tata.ev portfolio and building it largely on JLR’s EMA and Tata’s Gen 3 born-electric architectures. 

Published on 24-Dec-2025 09:08

Adani Ports acquires NQXT Australia.

Adani Ports and Special Economic Zone Limited (APSEZ) has completed the acquisition of a 100% interest in NQXT Australia. 

Published on 24-Dec-2025 09:07

L&T wins at least ₹5,000 cr EPC order from BPCL

Larsen & Toubro’s Hydrocarbon Onshore (L&T Onshore) business has secured a major EPC order (₹5,000–10,000 crore) from BPCL for setting up India’s largest LLDPE/HDPE swing unit (2 × 575 KTPA) at Bina, Madhya Pradesh, on a lump-sum turnkey basis. 

Published on 24-Dec-2025 09:06

Radico Khaitan launches premium dark rum The Kohinoor Reserve

Radico Khaitan (RKL) rolled out The Kohinoor Reserve Indian Dark Rum, a globally acclaimed, triple-aged rum matured in American Bourbon barrels, Cognac XO casks and Vermouth casks, a unique process that sets it apart in the global dark rum category. 

Published on 24-Dec-2025 09:05

ZF sells ADAS business to Harman International

ZF Friedrichshafen AG, the parent of ZF Commercial Vehicle Control Systems India (ZF CV), has agreed to sell its Advanced Driver Assistance Systems (ADAS) business, including compute platforms, smart cameras, radar and ADAS software, to US-based in-cabin electronics major Harman International for an enterprise value of €1.5 billion

Published on 24-Dec-2025 09:04

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Play Store App Store
market app
✕
Application status